CEL-SCI's Multikine shows 28% absolute 5-year survival benefit in head & neck cancer target population at ESMO

CEL SCI CORP

Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.
5-year survival 73% with Multikine vs 45% control (p=0.0015); hazard ratio 0.35, 65% risk reduction.
Pre-surgery disease downstaging observed in 35% of Multikine patients; linked to improved survival.
Pre-application regulatory filings submitted in UK and Europe; plans to file in US and Canada for immediate approval without confirmatory study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.